<DOC>
	<DOCNO>NCT02556866</DOCNO>
	<brief_summary>Multicenter randomize double-blind study compare efficacy safety rituximab combination corticosteroid corticosteroid plus placebo treatment non-infectious active mixed cryoglobulinemia vasculitis .</brief_summary>
	<brief_title>Rituximab Plus Corticosteroids Non-infectious Active Mixed Cryoglobulinemia Vasculitis</brief_title>
	<detailed_description>Cryoglobulinemia responsible systemic vasculitis , frequently target organ skin , joint , kidney peripheral nervous system . Cryoglobulinemia vasculitis associate significant morbidity mortality , require therapeutic intervention . Management non-infectious mixed cryoglobulinemia vasculitis base corticosteroid , plasma exchange , and/or immunosuppressant . These treatment associate frequent side effect . To date , study evaluate efficacy safety different therapeutic option , explain lack recommendation . Rituximab , monoclonal antibody direct CD20 , emerge novel therapeutic option B-cell related disorder . Data French AutoImmunity Rituximab ( AIR ) registry recently report positive effect rituximab non-infectious mixed cryoglobulinemia vasculitis . More recently , multidisciplinary national French CryoVas survey also suggest significant superiority combination corticosteroid plus rituximab compare corticosteroid alone term complete clinical immunological response corticosteroid spar . However , randomize control data address issue publish date .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . The patient must least 18 year age old , without upper age limit 2 . Patient inform agreed participate , give inform consent , 3 . Patient active cryoglobulinemia vasculitis define positive cryoglobulinemia clinically active vasculitis skin , joint , renal , peripheral nerve , central neurological , digestive , pulmonary and/or cardiac involvement ( histological evidence need presence purpura demonstrate ) , 4 . Patient primary Sj√∂gren 's syndrome , systemic lupus erythematosus , another autoimmune disease , Bcell nonHodgkin lymphoma ( cryoglobulinemia therapeutic indication ) , essential mixed cryoglobulinemia , 5 . Naive relapsing patient , without modification ( initiation increase ) immunosuppressive therapy month prior inclusion , 6 . For woman child bearing age : negative pregnancy test inclusion , effective contraception period 12 month late rituximab infusion placebo , 7 . Patients severe vasculitis must treat 15 day prior inclusion 3 bolus methylprednisolone ( 15 mg/kg/d ) AND 3 7 plasma exchange ( exchange volume 60 ml/kg/session ) . 1 . Patient medium small size vessel vasculitis unrelated cryoglobulinemia ( granulomatous polyangiitis ( Wegener 's disease ) , microscopic polyangiitis , eosinophilic granulomatous polyangiitis ( ChurgStrauss syndrome ) , polyarteritis nodose , IgA vasculitis , hypersensitivity vasculitis , infectious vasculitis , hypocomplementemic urticarial vasculitis ) , 2 . Patient large size vessel vasculitis , 3 . Patient non active cryoglobulinemia vasculitis , 4 . Patient immunosuppressive therapy introduce increased month prior inclusion , 5 . Patients receive corticosteroid therapy &gt; 0.5 mg/kg/d one month inclusion &gt; 1 mg/kg/d two week inclusion , 6 . Patient receive rituximab therapy within 12 month inclusion , 7 . Pregnancy progress need , breast feeding , 8 . HIVpositive status , 9 . Patient active hepatitis B C infection , 10 . HBs Agpositive and/or HBV DNA detectable blood* , 11 . Patients know hypersensitivity reaction active substance excipients , murine protein , 12 . Contraindication rituximab , 13 . Active infection screen , 14 . Patient guardianship , 15 . Patient already include biomedical research protocol , 16 . No social security scheme ( Beneficiaries eligible ) , 17 . History cancer last 3 year inclusion , include solid tumor , hematological malignancy ( except lymphoproliferative disorder associate mixed cryoglobulinemia vasculitis ) , carcinoma situ ( except basal cell squamous cell carcinoma skin treat excized cure ) '' If hepatitis B core antibody ( antiHBc ) positive , benefit/risk evaluate hepatologist inclusion , patient , enrol , monitor end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>